首页> 外国专利> Compounds (Piran - piperidinil) becimidazol, Pharmaceutical composition that comprises, their use for preparing a drug for the treatment of disorders mediated by M1 receptor agonism, processes for preparing compounds useful as Intermediates in the synthesis of the same.

Compounds (Piran - piperidinil) becimidazol, Pharmaceutical composition that comprises, their use for preparing a drug for the treatment of disorders mediated by M1 receptor agonism, processes for preparing compounds useful as Intermediates in the synthesis of the same.

机译:化合物(Piran-哌啶子醇)苯甲咪唑,药物组合物,其包括其在制备用于治疗由M1受体激动作用介导的疾病的药物中的用途,以及在其合成中用作中间体的化合物的制备方法。

摘要

Compound (Piran - piperidinil) benzimidazole formula (1) or a Salt or solvate thereof where: R5 is selected from Halogen, alkyl of C1 C1 - 6 - 6, alkyl substituted with one or more Atoms of F, 6 - alkoxy C1, C1 6 - alkoxy substituted with one or more Atoms of F, Select between R6 and cyano Halo; Hydrogen, alkyl C1 C1 - 6 - 6, alkyl substituted with one or more Atoms of F, cycloalkyl C3 - 6C3-6 cycloalkyl substituted with one or more Atoms of F, 6 - alkoxy C1, C1 6 - alkoxy substituted with one or more Atoms of F, and cyano; and q is H or alkyl of C1 - 6. Its use for preparing Medicine useful for Treatment of conditions requiring M1 agonism or psychotic Disorders and Cognitive Impairment.Processes of preparing Said Compound intermediary compounds used in the same.Claim 1: a process for preparing a compound of formula (1) or a Salt or solvate thereof as defined in claim 1, wherein Said process is selected from: (A1) coupling processes comprising a compound of formula (2) with a compound of formula (3) OJ R5 'is a group of R5 as defined in claim 1,Group or a convertible in R5 and R6 is a group R6 are as defined in claim 1, or a group Convertible in R6,Under appropriate conditions for Reductive Alkylation process; and (A2) comprising reacting a compound of formula (2) with a compound of formula (3) in the presence of a source of cyanide to form the intermediate ciano (30) that can be made to react with a Grignard Reagent of alqui The qmgx to form compounds of formula (1).Where R5 'is a group of R5 as defined in claim 1, or a group Convertible in R5 and R6 is a group R6 are as defined in claim 1, or a group Convertible in R6,And Q is C1 - 6 h or alkyl Grignard reactions under conditions appropriate for the process; and (b) that includes coupling a compound of formula (4) with a compound of formula (5) where R5 'is a group of R5 as defined in claim 1, or a group Convertible in R5 and R6 is a Group R6 as Defined in claim 1, or a group Convertible in R6,And Q is C1 - 6 H and alkyl; X and y represent the two groups outgoing optionally in an Inert Solvent, optionally in the presence of a base, optionally with Warming process; and (c) comprising treating a compound of formula (6) with a catalyst of Palladium or COPPER (vii) pa Ra an intramolecular cyclization.Where R5 'is a group of R5 as defined in claim 1, or a group Convertible in R5 and R6 is a group R6 are as defined in claim 1, or a group Convertible in R6, and q is H or alkyl of C1 - 6; and Z is a leaving Group such as BR rCL or triflate or process; (d) coupling comprising a compound of formula (7) with a compound of formula (9) where R5 'is a group of R5 as defined in claim 1, or a group Convertible in R5 and R6 is a group R6 as defined in claim 1 in a Group, or convertible R6,And Q is C1 - 6 h or alkyl; and R is an alkyl group C1 - 5 by heating in an Inert Solvent, e.g., xylene, followed by reduction of the double Bond of piperidine; and (e) process comprising reacting a compound of formula (10) with a Reagent / Combination of Reagents to perform The Curtius rearrangement of compound (10),Followed by intramolecular cyclization; where R5 'is a group of R5 as defined in claim 1, or a group Convertible in R5 and R6 is a group R6 are as defined in claim 1, or a group Convertible in R6,And Q is H or alkyl of C1 - 6; and (f) coupling process comprising a compound of formula (11) with a compound of formula (12) where R5 'is a group of R5 as defined in claim 1, or a group Convertible in R5 and R6 is a group R6 as defined in claim 1, or Group Co Nvertible R6,Q is H or alkyl of C1 - 6 and Z is Hydroxy or a leaving Group in terms of Alkylation reaction or Mitsunobu and Optionally, after that, for any of the above processes: Remove any Protective Group; and / or convert a compound of formula (1) or a Salt or solvate thereof In another Compound of formula (1) or a Salt or solvate thereof.Claim 1: a compound used as Intermediate in the process according to claim 1,Wherein is selected from: a compound of formula (2) or a Salt or solvate thereof; a compound of formula (30) or a Salt or solvate thereof; a compound of formula (4) or a Salt or solvate thereof; a compound of formula (6) or a Salt or solvate of the same; or a compound of fo Formula (10) or a Salt or solvate thereof; where R5 'is a group of R5 as defined in the reivindApplication 1, group or a convertible in R5 and R6 is a group R6 are as defined in claim 1, or a group Convertible in R6, Q is H or alkyl of C1 - 6, and Z is a leaving Group.
机译:式(1)的化合物(Piran-哌啶子醇)苯并咪唑或其盐或溶剂化物,其中:R5选自卤素,C1-6-6的烷基,被一个或多个F,6-烷氧基C1,C1的原子取代的烷基6-被一个或多个F原子取代的烷氧基,在R6和氰基卤素之间选择;氢,被一个或多个F原子取代的烷基C1至6-6烷基,被一个或多个F的原子取代的环烷基C3至6C3-6环烷基,被一个或多个F取代的6-烷氧基C1,C1-6烷氧基F和氰基原子;且q是H或C 1-6的烷基。其用于制备药物的用途,该药物可用于治疗需要M1激动或精神病和认知障碍的疾病。用于制备所述化合物的中间体的化合物的制备方法。权利要求1:制备方法2.根据权利要求1的式(1)化合物或其盐或溶剂化物,其中所述方法选自:(A1)包含式(2)化合物与式(3)化合物的偶联方法。在适当的还原烷基化工艺条件下,是如权利要求1所定义的R5基团,R5中的基团或可转化基团,R6是如权利要求1所定义的基团R6,或R6中的基团可转化基团。 (A2)包括使式(2)的化合物与式(3)的化合物在氰化物源的存在下反应,以形成可与α-己内酰胺的格氏试剂反应的中间体钢琴(30)。式中,R 5'是如权利要求1所定义的R 5的基团,或R 5中可转换的基团和R 6是如权利要求1所定义的基团R 6,或R 6是可转换的基团, Q是在适合该工艺的条件下进行的C1-6小时或烷基Grignard反应; (b)包括将式(4)的化合物与式(5)的化合物偶联,其中R 5'是如权利要求1所定义的R 5的基团,或在R 5和R 6中可转化的基团是如所定义的R 6的基团。在权利要求1中,或在R6中可转换的基团,并且Q是C1-6H和烷基。 X和y代表两个基团,它们任选地在惰性溶剂中,任选地在碱的存在下,任选地通过温热过程流出; (c)包括用钯或COPPER的催化剂在分子内环化处理式(6)的化合物。其中R5′是如权利要求1所定义的R5基团,或在R5中可转化的基团,和R6是权利要求1中所定义的基团R6或在R6中可转换的基团,并且q是H或C1-6的烷基; Z是离去基团,例如BR rCL或三氟甲磺酸酯或流程; (d)包含式(7)的化合物与式(9)的化合物的偶合,其中R 5'是如权利要求1所定义的R 5的基团,或在R 5和R 6中可转化的基团是如权利要求1所定义的基团一个基团中的1个或可转换的R6,且Q为C1-6h或烷基;通过在惰性溶剂(例如二甲苯)中加热,然后还原哌啶的双键,R为烷基C1-5。 (e)方法包括使式(10)的化合物与试剂/试剂的组合反应以进行化合物(10)的库尔修斯重排,随后进行分子内环化;其中R5′是权利要求1中定义的R5基团,或R5中可转换基团和R6是权利要求1中定义的基团R6,或R6中可转换基团,并且Q是H或C1-6的烷基; (f)偶联方法,其包括式(11)的化合物与式(12)的化合物,其中R 5'是如权利要求1所定义的R 5的基团,或在R 5和R 6中可转化的基团是如所定义的基团R 6 2.根据权利要求1所述的方法,或者在烷基化反应或Mitsunobu方面,基团Co可逆变的R6,Q是H或C1-6的烷基,并且Z是羟基或离去基团,并且任选地,在那之后,对于以上任何一种方法:去除任何保护基组;权利要求1:在权利要求1的方法中用作中间体的化合物,其中式(1)的化合物或其盐或溶剂化物转化为另一种式(1)的化合物或其盐或溶剂化物。选自:式(2)的化合物或其盐或溶剂化物;式(30)的化合物或其盐或溶剂化物;式(4)的化合物或其盐或溶剂化物;式(6)化合物或其盐或溶剂化物;式(10)的化合物或其盐或溶剂化物;其中R5'是reivindApplication 1中定义的R5的基团,R5中的基团或可转换基团,并且R6是R6的基团,如权利要求1所定义,或R6中的可转换基团,Q是H或C1-6的烷基,并且Z是离开的组。

著录项

  • 公开/公告号AR055667A1

    专利类型

  • 公开/公告日2007-08-29

    原文格式PDF

  • 申请/专利权人 GLAXO GROUP LIMITED;

    申请/专利号AR2006P104267

  • 发明设计人

    申请日2006-09-28

  • 分类号C07D405/14;A61K31/4439;A61P25/16;A61P25/18;A61P25/28;C07D405/14;C07D309/14;C07D211/58;C07D235/26;

  • 国家 AR

  • 入库时间 2022-08-21 20:59:36

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号